(2-benzoyl-3-methylphenyl)acetonitrile | 1085539-07-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-benzoyl-3-methylphenyl)acetonitrile
• 英文别名: 2-(2-benzoyl-3-methylphenyl)acetonitrile
• CAS: 1085539-07-6
• 化学式: C₁₆H₁₃NO
• 分子量: 235.285
• InChiKey: BJWVPGOSCFKGGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2-benzoyl-3-methylphenyl)acetonitrile 在 platinum(IV) oxide 盐酸 、 氢气 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 反应 72.0h， 生成 1-cyclohexyl-8-methyl-3,4-dihydroisoquinoline hydrochloride
  参考文献：
  名称：

  1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND

  摘要：

  公开号：

  EP2149560B1
• 作为产物：
  描述：

  2,6-二甲基苯甲酸 在 aluminum (III) chloride 、 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 、 乙醇 、 水 为溶剂， 反应 16.0h， 生成 (2-benzoyl-3-methylphenyl)acetonitrile
  参考文献：
  名称：

  Discovery of an 8-methoxytetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain without CYP inhibition liability

  摘要：

  In lead optimization efforts starting from the tetrahydroisoquinoline (S)-1, we identified 2-{[(2R)-2-hydroxypropyl]amino}-1-[(1S)-8-methoxy-1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl]ethanone((1S)-8t) as a novel orally active small-molecule N-type calcium channel blocker without CYP inhibition liability. CYP3A4 inhibition profile was improved by reducing the lipophilicity of compound (S)-1. Moreover, introduction of a methoxy group to the C-8 position of tetrahydroisoquinoline led to identification of (1S)-8t, which eliminated CYP2D6 inhibition liability. Oral administration of (1S)-8t exerted efficacy in a rat spinal nerve ligation (SNL) model of neuropathic pain with an ED50 value of 2.8 mg/kg. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.053

文献信息

• 1-substituted tetrahydroisoquinoline compound
  申请人：Astellas Pharma Inc.

  公开号：US08263607B2

  公开（公告）日：2012-09-11

  Provided is a compound useful as an N-type Ca2+ channel blocker. As a result of intensive studies of compounds having an action of blocking N-type Ca2+ channels, the present inventors found that a tetrahydroisoquinoline compound of the present invention having a substituent at the 1-position has an action of blocking the N-type Ca2+ channels, an antinociceptive pain action, an antineuropathic pain action, an abdominal pain-inhibitory action and an opioid-induced constipation-improving action, and the present invention has been completed based on these findings. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating various pains such as neuropathic pain and nociceptive pain, headaches such as migraine and cluster headache, central nervous system diseases such as anxiety, depression, epilepsy, cerebral stroke and restless legs syndrome, abdominal symptoms such as abdominal pain and abdominal distension, stool abnormalities such as diarrhea and constipation, digestive system diseases such as irritable bowel syndrome, urinary system diseases such as overactive bladder and interstitial cystitis, etc.

  提供的是一种作为N型Ca2+通道阻滞剂有用的化合物。由于对具有阻断N型Ca2+通道作用的化合物进行了深入研究，本发明人发现，本发明的四氢异喹啉化合物在1位具有取代基，具有阻断N型Ca2+通道、抗痛觉疼痛作用、抗神经痛作用、抑制腹痛作用和改善阿片类药物引起的便秘作用，基于这些发现完成了本发明。本发明的化合物可用作预防和/或治疗各种疼痛，如神经痛和伤害性疼痛、头痛，如偏头痛和集群头痛、中枢神经系统疾病，如焦虑、抑郁、癫痫、脑卒中和不宁腿综合征、腹部症状，如腹痛和腹胀、大便异常，如腹泻和便秘、消化系统疾病，如肠易激综合征、泌尿系统疾病，如过度活动膀胱和间质性膀胱炎等的药物组成物。
• US8263607B2
  申请人：——

  公开号：US8263607B2

  公开（公告）日：2012-09-11
• 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：EP2149560B1

  公开（公告）日：2015-05-13
• Discovery of an 8-methoxytetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain without CYP inhibition liability
  作者：Takashi Ogiyama、Koichi Yonezawa、Makoto Inoue、Naoko Katayama、Toshihiro Watanabe、Seiji Yoshimura、Takayasu Gotoh、Tetsuo Kiso、Akiko Koakutsu、Shuichiro Kakimoto、Jun-ichi Shishikura

  DOI：10.1016/j.bmc.2015.05.053

  日期：2015.8

  In lead optimization efforts starting from the tetrahydroisoquinoline (S)-1, we identified 2-[(2R)-2-hydroxypropyl]amino}-1-[(1S)-8-methoxy-1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl]ethanone((1S)-8t) as a novel orally active small-molecule N-type calcium channel blocker without CYP inhibition liability. CYP3A4 inhibition profile was improved by reducing the lipophilicity of compound (S)-1. Moreover, introduction of a methoxy group to the C-8 position of tetrahydroisoquinoline led to identification of (1S)-8t, which eliminated CYP2D6 inhibition liability. Oral administration of (1S)-8t exerted efficacy in a rat spinal nerve ligation (SNL) model of neuropathic pain with an ED50 value of 2.8 mg/kg. (C) 2015 Elsevier Ltd. All rights reserved.